Veklury Gets EMA All-Clear Over Kidney Problems, But Faces New Safety Review For Bradycardia
Obesity Medicine Amfepramone Also Under The Safety Spotlight
Executive Summary
The pharmacovigilance panel at the European Medicines Agency is examining a new safety signal associated with Gilead’s COVID-19 antiviral therapy.
You may also be interested in...
Observational Study Hurdles: From Data Blinding To Data Sharing
US FDA’s Robert Temple says the agency is very worried about ensuring investigators are blinded to the results of observational studies and is currently writing a guidance document to address this.
EMA Assessing If Kidney Injury In COVID-19 Patients Is Linked To Remdesivir
While an EU panel is examining reports of acute kidney injury in some COVID-19 patients taking remdesivir, researchers conducting a UK-based study are preparing to update their systematic benefit-risk analysis of the drug as and when more safety data becomes available.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.